Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder

A 52-week, open-label, multicenter study

Ronald N. Marcus, Randall Owen, George Manos, Raymond Mankoski, Lisa Kamen, Robert D. McQuade, William H. Carson, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Objective: Evaluate the long-term safety and tolerability of aripiprazole in the treatment of irritability in pediatric subjects (6-17 years) with autistic disorder. Method: A 52-week, open-label, flexibly dosed (2-15 mg/d) study of the safety and tolerability of aripiprazole in outpatients with a DSM-IV-TR diagnosis of autistic disorder who either had completed 1 of 2 antecedent, 8-week randomized trials or were enrolled de novo (ie, not treated in the randomized trials). Safety and tolerability measures included incidences of adverse events, extrapyramidal symptoms, weight, metabolic measures, vital signs, and other clinical assessments. Results: Subjects were enrolled between September 2006 and June 2009. Three hundred thirty subjects entered the treatment phase: 86 de novo, 174 prior aripiprazole, and 70 prior placebo. A total of 199 (60.3%) subjects completed 52 weeks of treatment. Adverse events were experienced by 286/330 subjects (86.7%). Common adverse events included weight increase, vomiting, nasopharyngitis, increased appetite, pyrexia, upper respiratory tract infection, and insomnia. Discontinuations due to adverse events occurred in 35/330 randomized subjects (10.6%) - most commonly aggression and weight increase. One patient discontinued from the study due to a laboratory-related adverse event (moderately increased alanine transaminase and aspartate transaminase). Nine subjects experienced serious adverse events - most frequently aggression. Extrapyramidal symptoms-related adverse events occurred in 48/330 subjects (14.5%) - most commonly tremor (3.0%), psychomotor hyperactivity (2.7%), akathisia (2.4%), and dyskinesia (not tardive, 2.4%). At > 9 months' aripiprazole exposure (n = 220), mean change in body weight z score was 0.33 and body mass index z score was 0.31. The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides. Conclusions: Aripiprazole was generally safe and well tolerated in the long-term treatment of irritability associated with autistic disorder in pediatric subjects. Weight should be proactively monitored during long-term treatment. Trial Registration: clinical trials.gov Identifier: NCT00365859.

Original languageEnglish (US)
Pages (from-to)1270-1276
Number of pages7
JournalJournal of Clinical Psychiatry
Volume72
Issue number9
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Autistic Disorder
Multicenter Studies
Pediatrics
Safety
Weights and Measures
Psychomotor Agitation
Aggression
Nasopharyngitis
Therapeutics
Body Weight Changes
Vital Signs
Sleep Initiation and Maintenance Disorders
Tremor
Appetite
Aspartate Aminotransferases
Alanine Transaminase
Diagnostic and Statistical Manual of Mental Disorders
Respiratory Tract Infections
LDL Cholesterol
HDL Cholesterol

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder : A 52-week, open-label, multicenter study. / Marcus, Ronald N.; Owen, Randall; Manos, George; Mankoski, Raymond; Kamen, Lisa; McQuade, Robert D.; Carson, William H.; Findling, Robert L.

In: Journal of Clinical Psychiatry, Vol. 72, No. 9, 2011, p. 1270-1276.

Research output: Contribution to journalArticle

Marcus, Ronald N. ; Owen, Randall ; Manos, George ; Mankoski, Raymond ; Kamen, Lisa ; McQuade, Robert D. ; Carson, William H. ; Findling, Robert L. / Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder : A 52-week, open-label, multicenter study. In: Journal of Clinical Psychiatry. 2011 ; Vol. 72, No. 9. pp. 1270-1276.
@article{3150c1c8748d41d59c34cdab627ebcfd,
title = "Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study",
abstract = "Objective: Evaluate the long-term safety and tolerability of aripiprazole in the treatment of irritability in pediatric subjects (6-17 years) with autistic disorder. Method: A 52-week, open-label, flexibly dosed (2-15 mg/d) study of the safety and tolerability of aripiprazole in outpatients with a DSM-IV-TR diagnosis of autistic disorder who either had completed 1 of 2 antecedent, 8-week randomized trials or were enrolled de novo (ie, not treated in the randomized trials). Safety and tolerability measures included incidences of adverse events, extrapyramidal symptoms, weight, metabolic measures, vital signs, and other clinical assessments. Results: Subjects were enrolled between September 2006 and June 2009. Three hundred thirty subjects entered the treatment phase: 86 de novo, 174 prior aripiprazole, and 70 prior placebo. A total of 199 (60.3{\%}) subjects completed 52 weeks of treatment. Adverse events were experienced by 286/330 subjects (86.7{\%}). Common adverse events included weight increase, vomiting, nasopharyngitis, increased appetite, pyrexia, upper respiratory tract infection, and insomnia. Discontinuations due to adverse events occurred in 35/330 randomized subjects (10.6{\%}) - most commonly aggression and weight increase. One patient discontinued from the study due to a laboratory-related adverse event (moderately increased alanine transaminase and aspartate transaminase). Nine subjects experienced serious adverse events - most frequently aggression. Extrapyramidal symptoms-related adverse events occurred in 48/330 subjects (14.5{\%}) - most commonly tremor (3.0{\%}), psychomotor hyperactivity (2.7{\%}), akathisia (2.4{\%}), and dyskinesia (not tardive, 2.4{\%}). At > 9 months' aripiprazole exposure (n = 220), mean change in body weight z score was 0.33 and body mass index z score was 0.31. The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2{\%} for glucose, 5{\%} for total cholesterol, 7{\%} for low-density lipoprotein cholesterol, 30{\%} for high-density lipoprotein cholesterol, and 5{\%} for triglycerides. Conclusions: Aripiprazole was generally safe and well tolerated in the long-term treatment of irritability associated with autistic disorder in pediatric subjects. Weight should be proactively monitored during long-term treatment. Trial Registration: clinical trials.gov Identifier: NCT00365859.",
author = "Marcus, {Ronald N.} and Randall Owen and George Manos and Raymond Mankoski and Lisa Kamen and McQuade, {Robert D.} and Carson, {William H.} and Findling, {Robert L}",
year = "2011",
doi = "10.4088/JCP.09m05933",
language = "English (US)",
volume = "72",
pages = "1270--1276",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "9",

}

TY - JOUR

T1 - Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder

T2 - A 52-week, open-label, multicenter study

AU - Marcus, Ronald N.

AU - Owen, Randall

AU - Manos, George

AU - Mankoski, Raymond

AU - Kamen, Lisa

AU - McQuade, Robert D.

AU - Carson, William H.

AU - Findling, Robert L

PY - 2011

Y1 - 2011

N2 - Objective: Evaluate the long-term safety and tolerability of aripiprazole in the treatment of irritability in pediatric subjects (6-17 years) with autistic disorder. Method: A 52-week, open-label, flexibly dosed (2-15 mg/d) study of the safety and tolerability of aripiprazole in outpatients with a DSM-IV-TR diagnosis of autistic disorder who either had completed 1 of 2 antecedent, 8-week randomized trials or were enrolled de novo (ie, not treated in the randomized trials). Safety and tolerability measures included incidences of adverse events, extrapyramidal symptoms, weight, metabolic measures, vital signs, and other clinical assessments. Results: Subjects were enrolled between September 2006 and June 2009. Three hundred thirty subjects entered the treatment phase: 86 de novo, 174 prior aripiprazole, and 70 prior placebo. A total of 199 (60.3%) subjects completed 52 weeks of treatment. Adverse events were experienced by 286/330 subjects (86.7%). Common adverse events included weight increase, vomiting, nasopharyngitis, increased appetite, pyrexia, upper respiratory tract infection, and insomnia. Discontinuations due to adverse events occurred in 35/330 randomized subjects (10.6%) - most commonly aggression and weight increase. One patient discontinued from the study due to a laboratory-related adverse event (moderately increased alanine transaminase and aspartate transaminase). Nine subjects experienced serious adverse events - most frequently aggression. Extrapyramidal symptoms-related adverse events occurred in 48/330 subjects (14.5%) - most commonly tremor (3.0%), psychomotor hyperactivity (2.7%), akathisia (2.4%), and dyskinesia (not tardive, 2.4%). At > 9 months' aripiprazole exposure (n = 220), mean change in body weight z score was 0.33 and body mass index z score was 0.31. The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides. Conclusions: Aripiprazole was generally safe and well tolerated in the long-term treatment of irritability associated with autistic disorder in pediatric subjects. Weight should be proactively monitored during long-term treatment. Trial Registration: clinical trials.gov Identifier: NCT00365859.

AB - Objective: Evaluate the long-term safety and tolerability of aripiprazole in the treatment of irritability in pediatric subjects (6-17 years) with autistic disorder. Method: A 52-week, open-label, flexibly dosed (2-15 mg/d) study of the safety and tolerability of aripiprazole in outpatients with a DSM-IV-TR diagnosis of autistic disorder who either had completed 1 of 2 antecedent, 8-week randomized trials or were enrolled de novo (ie, not treated in the randomized trials). Safety and tolerability measures included incidences of adverse events, extrapyramidal symptoms, weight, metabolic measures, vital signs, and other clinical assessments. Results: Subjects were enrolled between September 2006 and June 2009. Three hundred thirty subjects entered the treatment phase: 86 de novo, 174 prior aripiprazole, and 70 prior placebo. A total of 199 (60.3%) subjects completed 52 weeks of treatment. Adverse events were experienced by 286/330 subjects (86.7%). Common adverse events included weight increase, vomiting, nasopharyngitis, increased appetite, pyrexia, upper respiratory tract infection, and insomnia. Discontinuations due to adverse events occurred in 35/330 randomized subjects (10.6%) - most commonly aggression and weight increase. One patient discontinued from the study due to a laboratory-related adverse event (moderately increased alanine transaminase and aspartate transaminase). Nine subjects experienced serious adverse events - most frequently aggression. Extrapyramidal symptoms-related adverse events occurred in 48/330 subjects (14.5%) - most commonly tremor (3.0%), psychomotor hyperactivity (2.7%), akathisia (2.4%), and dyskinesia (not tardive, 2.4%). At > 9 months' aripiprazole exposure (n = 220), mean change in body weight z score was 0.33 and body mass index z score was 0.31. The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides. Conclusions: Aripiprazole was generally safe and well tolerated in the long-term treatment of irritability associated with autistic disorder in pediatric subjects. Weight should be proactively monitored during long-term treatment. Trial Registration: clinical trials.gov Identifier: NCT00365859.

UR - http://www.scopus.com/inward/record.url?scp=80052989828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052989828&partnerID=8YFLogxK

U2 - 10.4088/JCP.09m05933

DO - 10.4088/JCP.09m05933

M3 - Article

VL - 72

SP - 1270

EP - 1276

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 9

ER -